X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/olaratumab-antibody-licensed-from-lilly-demonstrates-proof-of-concept-as-a-theranostic-radiopharmaceutical-301798405.html
https://seekingalpha.com/news/3822270-eli-lilly-in-pact-with-australian-biotech-telix-for-cancer-therapy
https://seekingalpha.com/news/3822270-eli-lilly-in-pact-with-australian-biotech-telix-for-cancer-therapy
https://www.raps.org/news-and-articles/news-articles/2019/7/mercks-keytruda-is-first-to-add-indications-under
https://www.fiercepharma.com/pharma/amid-important-launches-lilly-s-bio-medicines-head-shaw-steps-aside
https://endpts.com/suffering-a-series-of-setbacks-eli-lillys-oncology-group-quietly-executes-2-of-its-top-mid-stage-drugs/
https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo
https://www.biopharmadive.com/news/lilly-to-withdraw-fda-approved-cancer-drug-after-clinical-failure/553443/
https://www.fiercepharma.com/pharma/lilly-hopes-to-keep-current-patients-as-lartruvo-exits-world-stage
https://www.reuters.com/article/us-lilly-results/eli-lilly-backs-u-s-proposal-on-drug-rebates-to-lower-costs-idUSKCN1PV196
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/68974a-eng.php
http://www.pmlive.com/pharma_news/ema_says_lillys_lartruvo_should_not_be_prescribed_1276071
https://www.raps.org/news-and-articles/news-articles/2019/1/ema-no-new-patients-should-start-treatment-with-l?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2023%20January
https://www.ema.europa.eu/en/news/no-new-patients-should-start-treatment-lartruvo-after-study-shows-cancer-medicine-does-not-prolong
https://pharmaphorum.com/news/lilly-pulls-cancer-drug-from-market-after-shock-trial-failure/
https://www.prnewswire.com/news-releases/apexigen-announces-clinical-collaboration-on-a-new-phase-2-trial-for-apx005m-in-sarcoma-300769282.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038
Market Place
Share 
